From USFDA
Cadila Healthcare announced that Zydus Cadila has received final approval from the US FDA to market Acyclovir Tablets in the strengths of 400 mg and 800 mg. The drug fall under the anti-viral segment.The estimated sales in 2014 for Acyclovir Tablets is USD 55.8 million, as per IMS.
The group now has 95 approvals and has filed so far 249 ANDAs since the commencement of filing process in FY 2003-04.
Powered by Capital Market - Live News
